AU2016255510A1 - 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto - Google Patents
1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto Download PDFInfo
- Publication number
- AU2016255510A1 AU2016255510A1 AU2016255510A AU2016255510A AU2016255510A1 AU 2016255510 A1 AU2016255510 A1 AU 2016255510A1 AU 2016255510 A AU2016255510 A AU 2016255510A AU 2016255510 A AU2016255510 A AU 2016255510A AU 2016255510 A1 AU2016255510 A1 AU 2016255510A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridin
- carboxamide
- indoline
- fluoro
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154523P | 2015-04-29 | 2015-04-29 | |
| US62/154,523 | 2015-04-29 | ||
| PCT/US2016/030105 WO2016176571A1 (en) | 2015-04-29 | 2016-04-29 | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016255510A1 true AU2016255510A1 (en) | 2017-11-23 |
Family
ID=56015108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016255510A Abandoned AU2016255510A1 (en) | 2015-04-29 | 2016-04-29 | 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9676758B2 (https=) |
| EP (1) | EP3292114B1 (https=) |
| JP (1) | JP6673939B2 (https=) |
| KR (1) | KR20180004193A (https=) |
| CN (1) | CN108174603B (https=) |
| AU (1) | AU2016255510A1 (https=) |
| BR (1) | BR112017022987A2 (https=) |
| CA (1) | CA2984153A1 (https=) |
| CL (1) | CL2017002738A1 (https=) |
| EA (1) | EA034244B1 (https=) |
| ES (1) | ES2784316T3 (https=) |
| IL (1) | IL255185A0 (https=) |
| MX (1) | MX373876B (https=) |
| PH (1) | PH12017501961A1 (https=) |
| WO (1) | WO2016176571A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111792990A (zh) * | 2019-04-09 | 2020-10-20 | 中国科学院上海药物研究所 | 一种不饱和酮类化合物、其制备方法和用途 |
| AU2020381168A1 (en) * | 2019-11-08 | 2022-04-14 | Nxera Pharma Uk Limited | GPR52 modulator compounds |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| BR112022018996A2 (pt) * | 2020-03-30 | 2022-11-01 | Boehringer Ingelheim Int | 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52". |
| WO2021216705A1 (en) * | 2020-04-22 | 2021-10-28 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| GB202013558D0 (en) | 2020-08-28 | 2020-10-14 | Heptares Therapeutics Ltd | GRP52 Modularor compounds |
| WO2022232017A1 (en) | 2021-04-26 | 2022-11-03 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| JP2024533565A (ja) | 2021-09-14 | 2024-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ３－フェノキシアゼチジン－１－イル－ヘテロアリールピロリジン誘導体及び医薬としてのその使用 |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| AR130864A1 (es) * | 2022-10-26 | 2025-01-29 | Neurocrine Biosciences Inc | Compuestos y composiciones como moduladores de gpr52 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| US20110009421A1 (en) * | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| JPWO2009157196A1 (ja) * | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| TW201010977A (en) | 2008-08-12 | 2010-03-16 | Takeda Pharmaceutical | Amide compound |
| US8481731B2 (en) * | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| JP2012082175A (ja) * | 2010-10-14 | 2012-04-26 | Daiichi Sankyo Co Ltd | インドリン化合物を含有する医薬組成物 |
-
2016
- 2016-04-29 CN CN201680038190.3A patent/CN108174603B/zh active Active
- 2016-04-29 MX MX2017013853A patent/MX373876B/es active IP Right Grant
- 2016-04-29 EA EA201792375A patent/EA034244B1/ru not_active IP Right Cessation
- 2016-04-29 KR KR1020177034516A patent/KR20180004193A/ko not_active Withdrawn
- 2016-04-29 AU AU2016255510A patent/AU2016255510A1/en not_active Abandoned
- 2016-04-29 US US15/143,026 patent/US9676758B2/en active Active
- 2016-04-29 BR BR112017022987A patent/BR112017022987A2/pt not_active Application Discontinuation
- 2016-04-29 CA CA2984153A patent/CA2984153A1/en not_active Abandoned
- 2016-04-29 EP EP16723592.8A patent/EP3292114B1/en active Active
- 2016-04-29 ES ES16723592T patent/ES2784316T3/es active Active
- 2016-04-29 JP JP2017556818A patent/JP6673939B2/ja active Active
- 2016-04-29 WO PCT/US2016/030105 patent/WO2016176571A1/en not_active Ceased
-
2017
- 2017-10-22 IL IL255185A patent/IL255185A0/en unknown
- 2017-10-27 PH PH12017501961A patent/PH12017501961A1/en unknown
- 2017-10-30 CL CL2017002738A patent/CL2017002738A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA034244B1 (ru) | 2020-01-21 |
| IL255185A0 (en) | 2017-12-31 |
| US20160318911A1 (en) | 2016-11-03 |
| EP3292114A1 (en) | 2018-03-14 |
| CA2984153A1 (en) | 2016-11-03 |
| EP3292114B1 (en) | 2020-03-11 |
| US9676758B2 (en) | 2017-06-13 |
| JP6673939B2 (ja) | 2020-04-01 |
| MX2017013853A (es) | 2018-06-07 |
| WO2016176571A1 (en) | 2016-11-03 |
| CL2017002738A1 (es) | 2018-06-01 |
| KR20180004193A (ko) | 2018-01-10 |
| ES2784316T3 (es) | 2020-09-24 |
| JP2018519253A (ja) | 2018-07-19 |
| BR112017022987A2 (pt) | 2018-07-24 |
| CN108174603A (zh) | 2018-06-15 |
| EA201792375A1 (ru) | 2018-05-31 |
| CN108174603B (zh) | 2021-07-02 |
| PH12017501961A1 (en) | 2018-03-26 |
| MX373876B (es) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3292114B1 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| TWI415845B (zh) | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 | |
| TWI473803B (zh) | 作為阿伐７正向異位調節劑之嗎福啉基噻唑 | |
| CA2770932C (en) | Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines | |
| JP2019031537A (ja) | エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体 | |
| RU2683245C1 (ru) | 6-членные гетероциклические производные и содержащая их фармацевтическая композиция | |
| RU2476433C2 (ru) | 1,3,5-тризамещенное производное триазола | |
| TW201307284A (zh) | 脂肪酸醯胺水解酶（ｆａａｈ）抑制劑 | |
| JP2014509660A (ja) | ＰＤＫ１キナーゼの阻害剤としての置換３−（１Ｈ−ベンゾ｛ｄ｝イミダゾール−２−イル）−１Ｈ−インダゾール類似体 | |
| JP2017503837A (ja) | ピリジン類及びピリミジン類並びにその使用 | |
| CA2652852A1 (fr) | Derives d'urees de piperidine ou pyrrolidine, leur preparation et leur application en therapeutique | |
| CZ20033053A3 (en) | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | |
| EP3981394A1 (en) | A sortilin antagonist for use in the prevention or treatment of hearing loss. | |
| WO2023031440A1 (en) | 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system | |
| TW201713629A (zh) | 新穎苯并咪唑化合物及其醫藥用途 | |
| IL293931A (en) | Oga inhibitor compounds | |
| KR20200091422A (ko) | 피리디논 유도체 및 선택적 alk-2 억제제로서의 그의 용도 | |
| KR20100031604A (ko) | 유로텐신 ｉｉ 수용체 길항제 | |
| JP7200258B2 (ja) | デュアルの５－ｈｔ２ａおよび５－ｈｔ６受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体 | |
| TWI564300B (zh) | 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑 | |
| EA011636B1 (ru) | Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda | |
| JP7385852B2 (ja) | Ｐ２ｘ３受容体のアンタゴニストとしてのｎ－カルボキサミドピラゾリン系誘導体及びその使用 | |
| EA010893B1 (ru) | Новые производные бензоилмочевины | |
| KR20240042472A (ko) | 무스카린성 수용체 4 길항제 및 사용 방법 | |
| EP4654972A1 (en) | Compounds and methods for yap/tead modulation and indications therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |